Photo: Depositphotos
Jul 29, 2025, 08:02
Promising Results from Yiviva’s Phase 2b Trial! – National Foundation for Cancer Research
National Foundation for Cancer Research shared a post on LinkedIn:
“Promising results from Yiviva’s Phase 2b trial!
Presented at both ASCO25 and ESMOGI25, YIV-906 combined with sorafenib significantly improved survival outcomes for patients with advanced hepatocellular carcinoma and chronic hepatitis B.
Patients in the YIV-906 arm saw:
- Median overall survival nearly doubled
- Improved time to tumor progression
- Better treatment tolerance
Backed by NFCR, AFCR, Yale, and others, YIV-906 represents a novel systems biology-based approach to enhancing cancer therapies.”
More post featuring NFCR on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 7, 2025, 16:47
Sep 7, 2025, 16:30
Sep 7, 2025, 16:25